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Glucocorticoids appear to control Na+ absorption in pulmonary epithelial cells via a mechanism dependent upon serum and
glucocorticoid-inducible kinase 1 (SGK1), a kinase that allows control over the surface abundance of epithelial Na+ channel
subunits (a-, b- and g-ENaC). However, not all data support this model and the present study re-evaluates this hypothesis in
order to clarify the mechanism that allows glucocorticoids to control ENaC activity.
EXPERIMENTAL APPROACH
Electrophysiological studies explored the effects of agents that suppress SGK1 activity upon glucocorticoid-induced ENaC
activity in H441 human airway epithelial cells, whilst analyses of extracted proteins explored the associated changes to the
activities of endogenous protein kinase substrates and the overall/surface expression of ENaC subunits.
KEY RESULTS
Although dexamethasone-induced (24 h) ENaC activity was dependent upon SGK1, prolonged exposure to this glucocorticoid
did not cause sustained activation of this kinase and neither did it induce a coordinated increase in the surface abundance of
a-, b- and g-ENaC. Brief (3 h) exposure to dexamethasone, on the other hand, did not evoke Na+ current but did activate
SGK1 and cause SGK1-dependent increases in the surface abundance of a-, b- and g-ENaC.
CONCLUSIONS AND IMPLICATIONS
Although glucocorticoids activated SGK1 and increased the surface abundance of a-, b- and g-ENaC, these responses were
transient and could not account for the sustained activation of ENaC. The maintenance of ENaC activity did, however,
depend upon SGK1 and this protein kinase must therefore play an important but permissive role in glucocorticoid-induced
ENaC activation.
Abbreviations
ENaC, epithelial sodium channel; IAmil, amiloride-sensitive component of the total membrane current; IAmil (-82 mV),
amiloride-sensitive membrane current flowing at -82 mV; Im, total membrane current; Nedd-4/2, neural precursor cell
expressed, developmentally down-regulated protein 4-2; NDRG1, protein encoded by n-myc downstream regulated
gene 1; P70-S6K, 70 kDa ribosomal S6 kinase; PDK1, 3-phosphoinositide-dependent protein kinase 1; PIP2,
phosphatidylinostiol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PKB, protein kinase B (also
known as Akt); PRAS40, 40 kDa proline-rich substrate of Akt (PKB); SGK1, serum and glucocorticoid-inducible kinase 1;
TORC1 and 2, target of rapamycin complex 1 and 2; VHold, holding potential; Vm, membrane potential
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Introduction
The controlled absorption of Na+ and water from the liquid
film that covers the lung and airway epithelia is critical to the
integrated functioning of the respiratory tract, and this
process depends upon epithelial Na+ channels (ENaC),
transport proteins composed of three subunits (a-, b- and
g-ENaC) that form the selective channels that allow electro-
genic Na+ entry in absorptive epithelia (Canessa et al., 1993;
1994; Knowles and Boucher, 2002; Matthay et al., 2002;
Boucher, 2007; channel nomenclature follows Alexander
et al., 2011). Glucocorticoids are physiologically important
regulators of this pulmonary Na+ transport process (see
Matalon and O’Brodovich, 1999; Matthay et al., 2002; Olver
et al., 2004) and such steroid hormones appear to control
ENaC via a mechanism dependent upon phosphoinositide-
3-kinase (PI3K), a regulatory kinase that catalyses the
formation of phospholipid second messengers, prima-
rily phosphatidylinositol -3,4,5- trisphosphate (PIP3) and
phosphatidylinositol-3,5-bisphosphate (PIP2). Early studies of
renal epithelia showed that PI3K inhibitors suppressed Na+
absorption, apparently by reducing the number of functional
Na+ channels in the apical membrane (Păunescu et al., 2000).
This control over the surface abundance of a-, b- and g-ENaC
is now attributed to serum and glucocorticoid-inducible
kinase 1 (SGK1), a PI3K-dependent protein kinase that
appears able to inhibit the removal of ENaC subunits from
the plasma membrane. Activation of SGK1 is therefore
thought to allow a-, b- and g-ENaC to remain in the mem-
brane leading to a rise in its Na+ conductance and increased
Na+ absorption (Blazer-Yost et al., 1998; 2003; Record et al.,
1998; De La Rosa et al., 1999; 2003; Păunescu et al., 2000;
Debonneville et al., 2001). However, not all data support this
hypothesis since sgk1 gene deletion causes only mild dysfunc-
tion of renal Na+ handling without preventing the hormonal
control of colonic Na+ absorption, and also fails to induce an
overt pulmonary phenotype (Wulff et al., 2002; Rexhepaj
et al., 2006; Fejes-Toth et al., 2008; Lang et al., 2009). More-
over, pharmacological inhibition of PI3K and/or SGK1 causes
only modest (10–20%) inhibition of basal Na+ transport in
mouse cortical collecting duct cells (Mansley and Wilson,
2010a,b).
The role of PI3K/SGK1 in the control of ENaC activity is
therefore not fully understood (Lang et al., 2009; Loffing and
Korbmacher, 2009) and, to some extent, this reflects the fact
that the PI3K inhibitors used in earlier studies (LY294002,
wortmannin) are now known to exert many non-specific
actions (Bain et al., 2007). Moreover, whilst it was clear that
the activation of SGK1 by PI3K is dependent upon
phosphoinositide-dependent protein kinase 1 (PDK1), a PI3K-
dependent protein kinase that catalyses the phosphorylation
of SGK1 at Thr256 (Kobayashi and Cohen, 1999; Park et al.,
1999; Bayascas and Alessi, 2005), it was also known that this
reaction required the prior phosphorylation of SGK1 at Ser422
and the kinase responsible for this critical event was
unknown (Kobayashi and Cohen, 1999; Park et al., 1999).
This situation has now been changed by the development of
a new generation of selective inhibitors of PI3K, such as PI103
(see Raynaud et al., 2007) and SGK1 (GSK659034; see Sherk
et al., 2008) and by the identification of the target of rapa-
mycin signalling complex 2 (TORC2) as the kinase respon-
sible for the phosphorylation of SGK1 at Ser422 (García-
Martínez and Alessi, 2008; Lu et al., 2010). Moreover,
pharmacological inhibitors of TORC2 are also available
(TORIN1, see Thoreen et al., 2009) and these provide an effec-
tive means of inactivating SGK1 (García-Martínez and Alessi,
2008; Thoreen et al., 2009; Mansley and Wilson, 2010a).
The present study takes advantage of these developments
in order to evaluate the role of PI3K – TORC2 – SGK1 pathway
in the glucocorticoid-induced activation of ENaC in an epi-
thelial cell line (H441) derived from the human distal airway
(see Lazrak and Matalon, 2003; Clunes et al., 2004; Ram-
minger et al., 2004; Brown et al., 2008; Lazrak et al., 2009;
Althaus et al., 2010).
Methods
Cell culture
H441 cells were routinely maintained in RPMI medium
supplemented with 8.5% foetal bovine serum (FBS), 8.5%
newborn calf serum, 2 mM glutamine, 5 mg·mL-1 transferrin,
5 ng·mL-1 selenium and an antibiotic/antimycotic mixture
(Sigma Chemical Co., Poole, Dorset, UK). For experimenta-
tion, cells were removed from culture flasks (trypsin/EDTA)
and were plated onto six-well plates (for analyses of extracted
protein) or glass cover slips (for electrophysiological studies).
Cells on six-well plates were grown to ~80% confluence (5–6
days) before the growth medium was replaced with a fully
defined medium identical to that described earlier except that
it contained 20 nM insulin and the serum components were
replaced with FBS (8.5%) that had been dialysed to remove
hormones/growth factors. Glucocorticoid-deprived cells were
maintained in this medium for ~24 h before being used in
experiments while dexamethasone-treated cells were exposed
to medium containing 0.2 mM dexamethasone, as detailed in
the text. Cells used in electrophysiological experiments were
maintained in standard growth medium until cellular attach-
ment occurred (2–3 h). The cells were then briefly washed,
and exposed to glucocorticoid-free or dexamethasone-
supplemented medium, as detailed in the text.
Electrophysiology
Membrane currents were recorded (Axopatch 200B amplifier,
Axon Digidata 1440A interface, pClamp 10 software, Axon
Instruments, Foster City, CA, USA) from cells held under
voltage clamp in the perforated patch recording configura-
tion (Horn and Marty, 1988) using amphotericin to gain
electrical access to the cell interior (Clunes et al., 2004). The
pipette filling solution contained (in mM) NaCl, 10; KCl, 18;
K gluconate, 92; MgCl2, 0.5; EGTA, 1; HEPES 10; its pH was
adjusted to 7.2 with KOH, which brought [K+] to 113.3 mM.
The standard bath solution contained (in mM) NaCl 140; KCl
4.5; MgCl2 1; CaCl2 2.5; HEPES, 10; glucose 5; its pH was
adjusted to 7.4 with NaOH, which brought [Na+] to
144.4 mM. Experiments were undertaken at room tempera-
ture (~22°C) and the equilibrium potential for Na+ (ENa) and
K+ (EK) were therefore 67.8 mV and -81.9 mV respectively.
Recordings were initiated once the access resistance (Ra) had
fallen to a stable value below 50 MW (10–15 min). Ra and
input capacitance (Cm) were monitored throughout each
BJPSGK1 and airway epithelial Na
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experiment and all presented data are from preparations in
which these parameters remained stable. We achieved
40–50% compensation of the voltage drop across Ra, and
because the lowest value of membrane resistance was
~0.5 GW, the residual error in the holding potential (VHold)
was always <~4%; this was assumed to be negligible. In all
experiments, the membrane currents evoked by ramp
changes in VHold (-113 mV to +87 mV, 2 s) were initially
recorded during exposure to the standard bath solution and
the measurement then repeated after 20–30-s exposure to
10 mM amiloride. The amiloride-sensitive component of the
total membrane current (IAmil) was isolated by digitally sub-
tracting the current that persisted in the presence of
amiloride from the corresponding record of control current.
Previous work from this laboratory has shown that selective
Na+ currents can only be recorded from H441 cells growing in
contact with each other (Brown et al., 2008) and the electro-
physiological data included in the present study are therefore
derived entirely from cells growing in groups of three to six
cells. The values of Cm measured under these conditions
ranged from 20–100 pF and, because the value of Cm mea-
sured in an initial study of cells growing singly was 28.8 pF 
5.2 pF (n = 10); this variability indicates that neighbouring
cells can be electrically coupled to each other. There was,
however, no obvious relationship between the magnitude of
Cm and the number of cells in each group. Indeed, in many
instances, we recorded low values of Cm from cells that were
clearly in contact with their neighbours, and the extent to
which the cells become electrically coupled to their neigh-
bours therefore appears to be variable. Thus the currents
reported in the present study flow across the membranes of
one to five cells and larger values of Cm were associated with
larger currents. To ensure that this variability did not contrib-
ute to the variability in the presented data, the magnitudes of
all recorded currents have been normalized to Cm (i.e.
expressed as pA/pF). For presentation, such data were scaled
to the mean value of Cm associated a single cell, so that the
presented data are shown as pA per average-sized cell. All
potentials are corrected for the liquid junction potntial
(-13 mV) between the bath and pipette solutions and cited
values of membrane potential (Vm) were inferred from the
value of VHold at which Im was zero. Data are presented as
mean  SEM and values of n denote the number of recordings
made from different cells; all protocols were repeated in cells
from at least three different passage numbers.
Phosphorylation of endogenous proteins
Cells on six-well plates were washed with ice-cold PBS and
scraped into ice-cold lysis buffer containing protease and
phosphatase inhibitors (1% Triton; 50 mM Tris – HCl, pH 7.5;
1 mM EGTA; 1 mM EDTA; 1 mM Na orthovanadate; 10 mM
glycerol phosphate; 50 mM NaF; 5 mM Na pyrophosphate;
270 mM sucrose; 0.1% b-mercaptoethanol; 1 Roche Mini Pro-
tease Inhibitor tablet per 10 mL). Lysates were then trans-
ferred to Eppendorf tubes, ultrasonicated to ensure complete
cellular disruption and their protein contents determined
using Bradford reagent. Aliquots of extracted protein were
reduced and denatured by heating (95°C, 5 min) in the pres-
ence of 5% b-mercapto-ethanol and 2% SDS and fractionated
on SDS-polyacrylamide gels. Fractionated proteins were then
transferred to Hybond-P membranes (GE Healthcare, Buck-
inghamshire, UK) that were probed using antibodies against
the Thr346/356/366-phosphorylated and total forms of the
protein encoded by the N-myc dowstream regulated gene 1
(NDRG1); the Ser473-phosphorylated, Thr308-phosphorylated
and total forms of protein kinase B (PKB); the Thr389-
phosphorylated and total forms of 70 kDa ribosomal S6
kinase (P70-S6K), and the Ser240-phosphorylated and total
forms of the 40 kDa proline-rich substrate of Akt/PKB
(PRAS40). The antibodies against NDRG1 and PRAS-40 were
generously made available by Prof. Sir Philip Cohen (MRC-
Protein Phosphorylation Unit, University of Dundee) and the
antibodies against PKB and P70-S6K were from Cell Signalling
(Hertfordshire, UK). Molecular weights of identified bands
were estimated by comparing their electrophoretic mobilities
with those of a series of protein standards.
Expression of ENaC subunits
Cells on six-well plates were placed on ice, extensively
washed with ice-cold PBS and then exposed (1 h at 4°C
with gentle agitation) to 10 mM sulfosuccinimidyl-2-
(biotinamido)-ethyl-1,3′dithioproprionate (EZ-Link Sulfo-
NHS-SS-Biotin, Pierce, Fisher Scientific, West Sussex, UK), a
reagent that covalently modifies proteins by attaching a
cleavable biotin moiety to amine groups in N-terminal amino
acid residues and in lysine side chains. The biotinylation
reaction was terminated with excess substrate (ice-cold
100 mM glycine) and the cells then lysed as described above.
All lysates were centrifuged at 14 000 x g for 30 min to pre-
cipitate cell debris/insoluble proteins, and the protein
content of the cleared samples determined using Bradford
reagent (Bio-Rad, Hemel Hempstead, UK). Protein that had
simply been extracted from the cells in this way is referred to
as ‘total cellular protein’. In an initial series of experiments,
aliquots (500 mg) of total protein were mixed with
streptavidin-coated agarose beads (Pierce, Fisher Scientific)
and allowed to equilibrate for 60 min at room temperature
with continual agitation. Streptavidin binds biotin with high
affinity and proteins that have been modified by exposure to
the sulpho-NHS-SS-biotin reagent will thus bind to these
beads. The beads were washed extensively to remove
unbound proteins and then heated to 95°C under strongly
reducing/denaturing conditions (5% b-mercapto-ethanol/2%
SDS) in order to cleave the disulphide bonds in the biotin
moiety and release bound proteins into solution. The protein
purified in this way is referred to as ‘biotinylated protein’.
Experiments (n = 8) in which the mass of biotinylated protein
that could be purified using a relatively large volume (500 mL)
of streptavidin-bead slurry was assayed using a protein assay
compatible with reducing/denaturing agents (RC–DC
reagent, Bio-Rad, Hemel Hempstead, UK), showed that 48.0 
0.7 mg of protein was recovered from an initial 500 mg aliquot.
Because the protein-binding capacity of the streptavidin-
coated beads is 1–3 mg·mL-1 per slurry, all subsequent experi-
ments used 150 mL of slurry to isolate the biotinylated protein
from 500 mg of total protein. Under these conditions, there is
an approximate threefold excess binding capacity and the
smaller bead volume allows the biotinylated proteins to be
released directly into 50 mL of the sample buffer used for
SDS-PAGE. Western analysis showed that b-actin was readily
detectable in 1 mg aliquots of total protein and, although
b-actin could also be detected in 20 mg aliquots of biotiny-
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lated protein, it was necessary to overexpose the blots in
order to detect this protein. Because b-actin is a cytoskeletal
protein that is confined to the inner leaflet of the plasma
membrane, this protein would be inaccessible to biotinyla-
tion reagents in the extracellular fluid. The presence of
b-actin in the biotinylated protein fraction thus shows that
this protein pool does contain some intracellular proteins.
However, densitometric analysis showed that the abundance
of b-actin in a 20 mg aliquot of biotinylated protein was ~30%
of the abundance measured in 1 mg of total protein. This
finding indicates that the surface biotinylation/streptavidin
binding protocol allows surface-exposed proteins to be iso-
lated with 98–99% purity, and this protein fraction is there-
fore referred to as the ‘surface protein’. In all subsequent
experiments, aliquots of total protein (40 mg) and of the
surface protein purified from 500 mg of total protein were
subject to Western blot analysis using antibodies against a-, b-
and g-ENaC, and b-actin. The antibody against a-ENaC was a
gift from Cystic Fibrosis Center, University of North Carolina
(Chapel Hill, NC, USA); the antibody against b-ENaC was
from Santa Cruz Biotechnology (Heidelberg, Germany),
while the g-ENaC and b-actin antibodies were from Sigma
Chemical Co.
Data analysis and experimental design
The results of experiments that simply explored the effects of
exposing cells to a single test substance were analysed using
Student’s t-test, while the data from experiments that fol-
lowed more complex protocols were analysed using one-way
ANOVA with a Bonferroni post hoc test. Experiments were
undertaken using strictly paired experimental designs in
which the control and experimental cells were harvested
from the same culture flasks and cultured in parallel. Care was
taken to ensure that the control and experimental cells were
subject to an identical series of solution changes, and none of
the effects reported here can therefore be attributed to varia-
tions in physical disturbance. Protein samples from control
and experimental cells were extracted and processed in par-
allel using identical reagents; fractionated on the same gels,
and Western blots probed using identical antibodies and
other reagents. For quantitative analysis, a computer scanner
was used to produce image files of each blot, and a standard
software package (ImageJ) was then used to quantify the
optical density of the bands corresponding to control/
experimental protein. Background subtraction was achieved
by subtracting the optical density measured for an identically
sized area of clear gel adjacent to the region of interest. In
order to present the pooled results from a series of experi-
ments, we first calculated the mean optical density for the
control samples. All individual data points were then normal-
ized to this mean value, and all such data are therefore pre-
sented as relative abundances. All presented images were
processed digitally and, although minor adjustments were
made to contrast/brightness, these changes were applied to
the entire image. No specific feature visible in any image has
therefore been enhanced, obscured, moved or introduced.
Materials
Amiloride, dexamethasone and rapamycin were from Sigma
Chemical Co., Poole, Dorset; PI103 from Merck KGaA, Darm-
stadt, Germany and GSK650394 from TOCRIS Bioscience,
Bristol, UK. TORIN1 was a kind gift from Prof David Sabatini
(Whitehead Institute for Biomedical Research, Cambridge,
Mass., USA).
Results
Dexamethasone-induced activation of ENaC
Analysis of the total membrane currents recorded from
glucocorticoid-deprived cells showed that the relationship
between Im and VHold was essentially linear at physiologically
relevant values of VHold but displayed outward rectification at
depolarized potentials (Figure 1A); Vm was normally ~-45 mV
(Figure 1A,C). Amiloride (10 mM) had no effect upon the total
membrane current recorded from such cells and therefore
caused no change in Vm (Figure 1A,C), and further analysis of
these data thus showed that IAmil (see Methods) was negligible
(Figure 1D). Studies of dexamethasone-treated (0.2 mM,
~24 h) cells, on the other hand, revealed relatively depolar-
ized values of Vm (Figure 1B,C) and these hormone-treated
cells displayed hyperpolarizing responses to 10 mM amiloride
(DVm ~-40 mV, Figure 1B); further analysis of these data
revealed an amiloride-sensitive component to the total mem-
brane current that reversed at a potential (~65 mV) close to
ENa (Figure 1D); this current (IAmil) is therefore Na+ selective.
Kinase inhibitors suppress the
phosphorylation of endogenous
protein substrates
Analysis of protein extracted from dexamethasone-treated
(0.2 mM, 24 h) cells revealed clearly detectible levels of Ser473-
phosphorylated (Figure 2A,B) and Thr308-phosphorylated
(Figure 2C,D) PKB and, because these residues are physiologi-
cal substrates for TORC2 and PDK1, respectively (Biondi et al.,
2001; Bayascas and Alessi, 2005), this result shows that these
PI3K-dependent protein kinases are active under these con-
ditions. Such analyses also revealed phosphorylation of
NDRG1-Thr346/356/366 (Figure 2E,F), PRAS40-Ser240 (not shown,
n = 3) and P70-S6K-Thr389 (not shown, n = 3) and, since these
residues are physiological substrates for SGK1, PKB and the
target of rapamycin signalling complex 1 (TORC1), respec-
tively (Kovacina et al., 2003; Murray et al., 2004; 2005; Proud,
2007), it is clear that these PI3K-dependent protein kinases
are also active in dexamethasone-treated cells. PI103 (0.5 mM,
3 h) appeared to cause a marked reduction in the cellular
abundance of Ser473-phosphorylated (Figure 2A) and Thr308-
phosphorylated (Figure 2C) PKB, and densitometric/
statistical analysis of the data from the entire series of such
experiments confirmed that these effects were statistically
significant (Figure 2B,D). Moreover, PI103 had no effect upon
the overall PKB expression level (Figure 2B,D) and therefore
causes virtually complete inactivation of TORC2 and PDK1.
PI103 also caused a marked fall in the abundance of Thr346/
356/366-phosphorylated NDRG1 without altering the overall
NDRG1 expression level (Figure 2E,F), and it is therefore clear
that this substance also inactivates SGK1. PI103 (0.5 mM, 3 h)
similarly suppressed the phosphorylation of PRAS40-Ser240
(n = 3, not shown) demonstrating inactivation of PKB. Rapa-
mycin (0.1 mM, 3 h), a highly selective inhibitor of TORC1
BJPSGK1 and airway epithelial Na
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(Bain et al., 2007) did not alter the phosphorylation status of
PKB-Ser473 (Figure 2A,B), PKB-Thr308 (Figure 2C,D) or NDRG1-
Thr346/356/366 (Figure 2E,F) but did suppress the phosphoryla-
tion of P70-S6K-Thr389 (not shown, n = 3), a TORC1 substrate
(Proud, 2007) indicating essentially inactivation of this
protein kinase. GSK650394 (10 mM, 3 h) had no effect upon
the phosphorylation of PKB-Ser473 (Figure 2A,B), PKB-Thr308
(Figure 2C,D) or PRAS40-Ser240 (n = 3, not shown) but
did suppress the phosphorylation of NDRG1-Thr346/356/366
(Figure 2E,F) indicating selective inactivation of SGK1.
TORIN1, a recently developed inhibitor of TORC1 and
TORC2 (Thoreen et al., 2009), caused a concentration-
dependent fall in the abundance of Ser473-phosphorylated
PKB that occurred without influencing the overall PKB
expression level, and this effect was complete at 0.1 mM
(Figure 3A,B). While high concentration of TORIN1 also sig-
nificantly suppressed the phosphorylation of PKB-Thr308, this
effect (~50% inhibition, Figure 3C,D) was smaller (P < 0.001,
Student’s t-test) than the effect on PKB-Ser473 (~90% inhibi-
tion, Figure 3A,B), and statistical analysis of these data con-
firmed (P < 0.05) that TORIN1 inhibited the phosphorylation
of PKB-Ser473 more effectively than it suppressed the phospho-
rylation of PKB-Thr308. TORIN1 (0.1 mM, 3 h) also virtually
abolished the phosphorylation of NDRG1-Thr346/356/366
(Figure 3E,F) and, because rapamycin had no such effect
(Figure 2E,F), this apparent inactivation of SGK1 must reflect
inhibition of TORC2.
Dexamethasone-induced Na+ currents are
dependent on the PI3K–TORC2–SGK1
pathway
In a further series of electrophysiological studies, total
membrane currents were again recorded from cells that had
been exposed to 0.2 mM dexamethasone for ~24 h (n = 5).
Analysis of these data confirmed (see earlier) that such
dexamethasone-treated cells display depolarized values of Vm
(0.4  8.1 mV), and analysis of the total membrane currents
recorded after 10–30 s exposure to 10 mM amiloride showed
that Vm had fallen to -67.1  9.2 mV (P < 0.001). These data
thus confirm that this ENaC blocker hyperpolarizes
dexamethasone-stimulated cells and further analysis
(Figure 4A) revealed an amiloride-sensitive component to the
total membrane current essentially identical to that described
earlier; the magnitude of the amiloride-sensitive current
flowing at EK (IAmil(-82 mV)) was approximately -50 pA per cell
(Figure 4E). Parallel experiments (n = 6) in which total mem-
brane currents were recorded from dexamethasone-treated
(0.2 mM, ~24 h) cells that had been exposed to 0.5 mM PI103
for 3–4 h showed that this inhibitor of PI3K hyperpolarized
Vm to -51.0  6.0 mV (P < 0.001), and amiloride had no effect
Figure 1
Prolonged (24 h) exposure to dexamethasone activates epithelial Na+ channels (ENaC). (A) Relationships (n = 12, Cm = 45.7  5.2 pF; Ra = 22.2
 4.1 MW) between total membrane current (Im) and holding potential (VHold) quantified in glucocorticoid-deprived cells during exposure to the
standard extracellular solution (ECS) and after 20–30 s exposure to 10 mM amiloride (+Amil.). (B) Equivalent data from dexamethasone-treated
(0.2 mM, ~24 h) cells (n = 9, Cm = 47.6  8.0 pF; Ra = 28.9  3.1 MW). (C) Values of membrane potential (Vm) derived by analysis of the data in
A and B (means  SEM). ***P < 0.001, significant effects of amiloride, Student’s paired t–test. †P < 0.05, significant effect of dexamethasone,
one-way ANOVA with Bonferroni post hoc test. (D). The amiloride-sensitive component of the total membrane current (IAmil) was isolated by further
analysis of the data in A (Gluc.-deprived) and B (Dex.-treated) and has been plotted against VHold.
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Figure 2
Phosphorylation status of endogenous kinase substrates. Control (Cont) cells were maintained in dexamethasone-containing (0.2 mM) medium
for 24 h before being used in experiments while inhibitor-treated cells were exposed to 0.5 mM PI103 (PI103, n = 11), 0.1 mM rapamycin (Rap.,
n = 8) or 10 mM GSK650394 (GSK, n = 4) for the final 3 h of this incubation period. Aliquots of extracted protein (40 mg) were then subject to
Western analysis using antibodies against (A, B) Ser473-phosphorylated/total protein kinase B (P-PKB-Ser473/T-PKB); (C, D) Thr308-phosphorylated/
total PKB (P-PKB-Thr308/T-PKB), and (E, F) Thr346/356/366-phosphorylated/total n-myc downstream regulated gene 1 protein (P-NDRG1-Thr346/356/
366/T-NDRG1). A, C and E each show representative blots from single experiments while B, D and F present the pooled data obtained by
densitometric analysis of the entire series of experiments (means  SEM). ***P < 0.01; **P < 0.02, significantly different from control, Student’s
paired t-test.
Figure 3
Effects of TORIN1. Dexamethasone-treated (0.2 mM, 24 h) cells were either maintained under control conditions or exposed to TORIN1
(3–100 nM) for the final 3 h of this incubation period. Aliquots of protein extracted from control and TORIN1-treated cells (n = 5 for each) were
then analysed by Western blotting using antibodies against Ser473-phosphorylated/total protein kinase B (P-PKB-Ser473/T-PKB, A, B), Thr308-
phosphorylated/total PKB (P-PKB-Thr308/T-PKB, C, D) and Thr346/356/366-phosphorylated/total protein encoded by n-myc downstream regulated
gene 1 (P-NDRG1-Thr346/356/366/T-NDRG1, E, F). A, C and E show representative blots from single experiments while B, D and F show pooled data
derived from densitometric analysis of the entire series of experiments (mean  SEM). ***P < 0.01, **P < 0.05, one-way ANOVA with Bonferroni
post hoc test.; †P < 0.05, Student’s paired t–test; significant effects of TORIN1.
BJPSGK1 and airway epithelial Na
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upon the currents recorded under these conditions and thus
caused no change in Vm (DVm = -6.3  3.6 mV). Further
analysis showed that PI103 abolished the amiloride-sensitive
Na+-current that is normally seen in dexamethasone-treated
cells (Figure 4A,E). Exposing dexamethasone-treated cells to
rapamycin (0.1 mM, 3–4 h), on the other hand, did not alter
Vm (control: -3.9  5.3 mV, n = 4; rapamycin: -9.8  4.2 mV,
n = 4); did not modify the response to amiloride (control: DVm
= -62.9  10.2 mV; rapamycin: DVm = -36.7  17.4 mV), and
did not suppress the amiloride-sensitive Na+ current
(Figure 4B,E). TORIN1 (0.1 mM, 3–4 h) mimicked the effects
of PI103 by hyperpolarizing Vm (control: 8.3  8.7 mV, n = 4;
TORIN1: -58.5  9.0 mV, n = 4, P < 0.05), abolishing the
hyperpolarizing response to amiloride (control: DVm = -67.6
 19.6 mV; TORIN1: DVm = -8.3  7.8 mV, P < 0.05) and
essentially abolishing dexamethasone-induced, amiloride-
sensitive Na+ current (Figure 4C,E). Similarly, GSK650394
(10 mM, 3–4 h) also hyperpolarized Vm (control: -10.3 
Figure 4
Dexamethasone-induced Na+ currents – effects of kinase inhibitors. Total membrane currents (Im) were recorded both under standard conditions
and after 10–30 s exposure to 10 mM amiloride. The amiloride-sensitive component of the total membrane current (IAmil) was then isolated by
digitally subtracting the current that persisted in the presence of amiloride from the corresponding record of control current, and plotted (mean
 SEM) against VHold. (A) Data from cells exposed to 0.2 mM dexamethasone for ~24 h under control conditions, and from cells that had also been
exposed to 0.5 mM PI103 for the final 3–4 h of this incubation period (control: n = 5, Cm = 55.3  10.8 pF; Ra = 27.5  11.9 MW; PI103-treated:
n = 6, Cm = 46.2  9.3 pF; Ra = 32.8  8.4 MW). (B) Data from experiments that used an identical protocol to explore the effects of 0.1 mM
rapamycin (3–4 h) upon IAmil in dexamethasone-treated (0.2 mM, ~24 h) cells (control: n = 4, Cm = 67.4  13.4 pF; Ra = 27.8  10.8 MW;
rapamycin-treated: n = 5, Cm = 79.3  19.3 pF; Ra = 30.7  4.1 MW). (C) Analogous data showing the effects of 0.1 mM TORIN1 (control: n =
4, Cm = 39.9  10.1 pF; Ra = 20.1  3.9 MW; TORIN1-treated: n = 4, Cm = 40.5  5.8 pF; Ra = 33.1  6.9 MW). (D) Analogous data showing the
effects of 10 mM GSK650394 (control: n = 5, Cm = 69.7  11.7 pF; Ra = 39.4  10.1 MW; GSK650394-treated: n = 4, Cm = 35.4  2.9 pF; Ra =
39.8  11.8 MW). (E) Pooled data showing the amiloride-sensitive currents flowing at -82 mV (IAmil (-82 mV), mean  SEM) quantified in control (i.e.
0.2 mM dexamethasone, ~24 h) and inhibitor-treated (3–4 h) cells. ***P < 0.001, significantly different from appropriate control, Student’s t-test.
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6.2 mV, n = 5; GSK650394: -38.0  3.1 mV, n = 4, P < 0.001);
abolished the response to amiloride (control: DVm = -55.6 
12.2 mV; GSK650394: DVm = -1.6  1.7 mV, P < 0.001)
and abolished the dexamethasone-induced Na+ current
(Figure 4D,E).
Dexamethasone-induced ENaC expression
The a-ENaC antibody consistently detected two bands (~95
and ~75 kDa) in the total and the surface protein pools (see
Methods) and a direct comparison of protein extracted from
glucocorticoid-deprived and dexamethasone-stimulated cells
(0.2 mM, 24 h) showed that this synthetic glucocorticoid
increased the overall abundance of both forms of a-ENaC
(Figure 5A,E). Dexamethasone also increased the surface
abundance of both forms of a-ENaC, and these changes were
similar in magnitude to the effects on overall expression
(Figure 5A,E). The antibody against b-ENaC revealed a single
band at ~100 kDa that was present in both the total and the
surface protein pools and, although dexamethasone (0.2 mM,
24 h) significantly increased the overall abundance of this
protein, this synthetic glucocorticoid had no effect upon the
surface abundance of b-ENaC (Figure 5B,F). The g-ENaC anti-
body identified two bands (~90 and ~75 kDa) in total protein
but only the ~75 kDa form of g-ENaC was present at the cell
surface (Figure 5C,G). Although dexamethasone (0.2 mM,
24 h) had no discernible effect upon the pattern of g-ENaC
expression, it did cause a small but significant increase in
the surface abundance of the 75 kDa form of g-ENaC
(Figure 5C,G).
Effects of kinase inhibitors on the expression
of ENaC subunits in dexamethasone-
stimulated cells
Figures 6–9 show the results of experiments that used a
strictly paired experimental protocol to study the effects of
protein kinase inhibitors (3 h) upon the pattern of a-, b- and
g-ENaC expression in dexamethasone-stimulated (0.2 mM,
24 h) cells. The control data in these figures confirm the
pattern of expression described earlier. PI103 (0.5 mM,
Figure 6), rapamycin (0.1 mM, Figure 7), TORIN1 (0.1 mM,
Figure 8) and GSK650394 (10 mM, Figure 9) all reduced the
overall abundance of the 95 kDa form of a-ENaC, and these
effects were accompanied by corresponding reductions in the
surface abundance of this channel subunit. However, these
substances did not alter the abundance of the 75 kDa form of
a-ENaC in the total or the surface-exposed protein pools
(Figures 6–9). The kinase inhibitors also had no effect upon
the abundance of b-ENaC in either the total or the surface-
exposed protein pools and also failed to alter the overall
abundance of g-ENaC (Figures 6–9). However, PI103
(Figure 6), TORIN1 (Figure 8) and GSK650394 (Figure 9) all
reduced the amount of the 75 kDa form of g-ENaC that was
Figure 5
Effects of prolonged (~24 h) exposure to 0.2 mM dexamethasone upon the expression of epithelial Na+ channel a, b and g subunits (a-, b- and
g-ENaC). (A) Western blots showing the abundance of a-ENaC in aliquots of total (40 mg) and surface-exposed (purified from 500 mg of total
protein) protein derived from glucocorticoid-deprived and dexamethasone-treated (0.2 mM, ~24 h) cells. Analogous data for b- (B), g-ENaC (C)
and b-actin (D) are also presented. (E–G) Densitometric analyses showing the pooled results from five independent experiments. *P < 0.05;
**P < 0.001; ***P < 0.005, significant effects of dexamethasone, Student’s paired t-test.
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present at the cell surface. Rapamycin, on the other hand, did
not alter the pattern of g-ENaC expression (Figure 7).
Dexamethasone-induced activation of SGK1
is transient
The data in Figure 10A confirm (Inglis et al., 2009) that dex-
amethasone activates SGK1 (i.e. evokes phosphorylation of
NDRG1-Thr346/356/366). This response became apparent after
~30 min and persisted for at least 6 h (Figure 10A,B).
Although SGK1 activity is dependent upon the TORC2-
catalysed phosphorylation of SGK1-Ser422 (Kobayashi and
Cohen, 1999; Park et al., 1999; García-Martínez and Alessi,
2008), these experiments also showed that dexamethasone
(0.2 mM, 0–6 h) had no significant effect upon the phospho-
rylation of PKB-Ser473 (Figure 10C,D) an endogenous TORC2
substrate (Sarbassov et al., 2005). It is therefore clear that this
synthetic glucocorticoid increases cellular SGK1 activity
without activating the PI3K – TORC2 pathway. A further
series of experiments confirmed that brief (3 h) exposure to
dexamethasone (0.2 mM) activated SGK1 (Figure 10E,F) but
not TORC2 (Figure 10G,H), but also showed that prolonged
(24 h) exposure to dexamethasone had no effect upon the
phosphorylation status of NDRG1-Thr346/356/366 (Figure 10E,F)
or PKB-Ser473 (Figure 10G,H). Although dexamethasone
clearly activates SGK1, the present data indicate that SGK1
activity returns to its basal level after 24 h of continuous
stimulation.
Brief (3 h) exposure to dexamethasone
As the glucocorticoid-induced activation of SGK1 peaked at
~3 h (Figure 10), we also explored the effects of such rela-
tively brief stimulation with dexamethasone upon the surface
abundance of a-, b- and g-ENaC. Western blot analysis con-
firmed that b-actin was virtually undetectable (not shown,
n = 4) in the surface-exposed proteins derived from 500 mg of
total protein (see Methods), a result that confirms that the
biotinylation/streptavidin-binding protocol allows this
protein pool to be isolated with high purity. These studies
also confirmed that a-ENaC (~95 kDa and ~75 kDa), b-ENaC
(~100 kDa) and g-ENaC (~75 kDa) are all present in the
plasma membranes of glucocorticoid-deprived cells (Fig-
ure 11). More importantly, these experiments clearly showed
that brief (i.e. 3 h) stimulation with dexamethasone caused
an unambiguous increase in the surface abundance of each of
these subunits (Figure 11). Moreover, this response was abol-
ished by GSK650394 (10 mM), and it is therefore clear that
Figure 6
Effects of P1103 upon a-, b- and g-ENaC expression in dexamethasone-treated cells. Total and surface-exposed proteins were extracted from
dexamethasone-treated (0.2 mM, ~24 h) cells that had either been maintained under control conditions or exposed to 0.5 mM PI103 for the final
3 h of the incubation period. The surface-exposed proteins purified from 500 mg aliquots of total protein were fractionated (SDS-PAGE) in parallel
with 40 mg aliquots of total protein, and subject to Western analysis using antibodies against a-ENaC, b-ENaC, g-ENaC and b-actin. (A) Western
blot showing data from an individual experiment; bars to the right indicate the approximate position of the appropriate molecular weight markers.
(B) Densitometric analysis showing the pooled data from four independent experiments (mean  SEM). *P < 0.05, significant effects of PI103,
Student’s paired t-test.
BJP GB Watt et al.
1280 British Journal of Pharmacology (2012) 166 1272–1289
brief (3 h) exposure to dexamethasone induces an SGK1-
dependent increase in the surface abundance of a-, b- and
g-ENaC (Figure 11). This observation prompted a further
series of electrophysiological studies that used a strictly
paired experimental design to compare the effects of brief
(3–4 h) and prolonged (~24 h) exposure to dexamethasone
(0.2 mM) upon the activity of ENaC. Analysis of the total
membrane currents recorded from these cells confirmed that
glucocorticoid-deprived cells (n = 3) displayed hyperpolarized
values of Vm (-64.4  4.2 mV) that were insensitive to 10 mM
amiloride (DVm = -0.2  1.5 mV), and IAmil was therefore
negligible (Figure 12). Moreover, experiments undertaken
using cells that had been exposed to dexamethasone for ~3 h
revealed essentially identical values of Vm (-60.8  7.2 mV)
and these cells, in common with the glucocorticoid-deprived
cells, were insensitive to amiloride (DVm = -0.5  0.7 mV) and
did not display discernible Na+ currents (Figure 12). However,
parallel studies of cells that had been stimulated with dexam-
ethasone for ~24 h revealed depolarized values of Vm (-7.9 
7.3 mV) that differed significantly from the values measured
in glucocorticoid-deprived cells and in cells that had been
exposed to dexamethasone for only 3 h (P < 0.05, one-way
ANOVA/Bonferroni post hoc test). Moreover, these cells dis-
played hyperpolarizing responses to 10 mM amiloride (DVm =
-57.8  0.7 mV, P < 0.005, Student’s paired t-test) and further
analysis (Figure 12) revealed amiloride-sensitive Na+ currents
essentially identical to those described earlier.
Discussion
Dexamethasone depolarized H441 cells by activating an
endogenous conductance essentially identical to that associ-
ated with co-expression of a-, b- and g-ENaC and this obser-
vation confirms (see Lazrak and Matalon, 2003; Clunes et al.,
2004; Brown et al., 2008; Althaus et al., 2010) that ENaC
activity in these cells is strictly dependent upon glucocorti-
coid stimulation. Glucocorticoids are physiologically impor-
tant regulators of pulmonary Na+ transport and, since these
hormones stimulate the removal of fluid from the alveolar
space (Matalon and O’Brodovich, 1999; Matthay et al., 2002;
Olver et al., 2004), synthetic glucocorticoids are used in the
clinical management of conditions such as neonatal respira-
tory distress syndrome and pulmonary oedema that are char-
acterized by the accumulation of liquid in this region of the
lung. Moreover, as glucocorticoids also exert powerful anti-
inflammatory actions, glucocorticoid receptor agonists are
also used in the treatment of lung diseases such as asthma
and chronic obstructive pulmonary disease that are charac-
terized by chronic inflammation (Barnes, 2011). It is therefore
Figure 7
Effects of rapamycin upon a-, b- and g-ENaC expression in dexamethasone-treated (0.2 mM, ~24 h) cells. Total and surface-exposed proteins were
extracted from dexamethasone-treated (0.2 mM, ~24 h) control cells and from dexamethasone-treated cells that had been exposed to 0.1 mM
rapamycin for the final 3 h of the incubation period, and analysed as described in Figure 5. (A) Western blot showing data from an individual
experiment; bars to the right indicate the approximate position of the appropriate molecular weight markers. (B) Densitometric analysis showing
the pooled data from four independent experiments (mean  SEM). *P < 0.05, significant effects of rapamycin, Student’s paired t-test.
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important to understand the mechanisms that allow pulmo-
nary epithelial cells to respond to these hormones and, in
order to study the mechanisms that underlie the activation of
endogenous ENaC, we have now explored the effects of low
MW inhibitors of various kinases upon the dexamethasone-
dependent Na+ currents seen in these cells. However, this
approach is complicated by the fact that such compounds
almost invariably act upon multiple targets (Bain et al., 2007)
and we therefore also used phospho-specific antibodies to
monitor the phosphorylation status of endogenous kinase
substrates in order to ensure that the tested compounds
caused full inhibition of their targets without inactivating
other, closely related kinases.
Effects of kinase inhibitors
Analysis of proteins extracted from dexamethasone-
stimulated cells showed that PDK1 and TORC2 were both
active and, since these kinases depend upon the presence of
PIP2/3 in the plasma membrane (Biondi et al., 2001; Bayascas
and Alessi, 2005; García-Martínez and Alessi, 2008), this
result also suggests that PI3K is active under these conditions.
These studies revealed the activity of SGK1 and PKB and this
was anticipated because these regulatory kinases lie down-
stream of PI3K – TORC2/PDK1 (Kobayashi and Cohen, 1999;
Park et al., 1999; Biondi et al., 2001; Bayascas and Alessi,
2005; Sarbassov et al., 2005; García-Martínez and Alessi,
2008). PI103 caused inactivation of PDK1, TORC2, SGK1 and
PKB, and this broad action is consistent with selective inhi-
bition of PI3K since the inactivation of this phospholipid
kinase would deplete the membrane of PIP2/3 leading to inac-
tivation of PDK1 and TORC2. This effect, in turn, would
inactivate SGK1 and PKB (Kobayashi and Cohen, 1999; Park
et al., 1999; Bayascas and Alessi, 2005; Sarbassov et al., 2005;
García-Martínez and Alessi, 2008). Although PI103 is known
to inhibit TORC1 as well as PI3K (Bain et al., 2007; Raynaud
et al., 2007), this cannot explain the present data because
rapamycin, a highly selective TORC1 inhibitor (Bain et al.,
2007), did not mimic the effects of PI103 despite causing
essentially complete inactivation of TORC1. Therefore, PI103
provides an effective means of inhibiting PI3K in H441 cells
and the fact that PI103, but not rapamycin, abolished the
dexamethasone-induced Na+ current shows that glucocorti-
coids control ENaC via a PI3K-dependent mechanism. This
conclusion is consistent with previous studies (Blazer-Yost
et al., 1998; 2003; Record et al., 1998; De La Rosa et al., 1999;
2003; Păunescu et al., 2000; Debonneville et al., 2001; Inglis
et al., 2009).
In order to study the physiological basis of this require-
ment for PI3K our subsequent experiments explored the
effects of TORIN1 a compound that inhibits TORC2, the
protein kinase that allows PI3K to control both PKB and SGK1
Figure 8
Effects of TORIN1 upon a-, b- and g-ENaC expression in dexamethasone-treated (0.2 mM, ~24 h) cells. Total and surface-exposed proteins were
from dexamethasone-treated (0.2 mM, ~24 h) control cells and from cells exposed to 0.1 mM TORIN1 for the final 3 h of the incubation period
were analysed as described in Figure 5 (A) Western blot showing the results of an individual experiment; bars to the right indicate the approximate
position of the appropriate molecular weight markers. (B) Densitometric analysis showing the pooled data from four independent experiments
(mean  sSEM). *P < 0.05, significant effects of TORIN1, Student’s paired t-test.
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(Sarbassov et al., 2005; García-Martínez and Alessi, 2008;
Thoreen et al., 2009). When used at 0.1 mM, TORIN1 virtually
abolished the phosphorylation of PKB-Ser473, indicating full
inactivation of TORC2, but also suppressed the phosphoryla-
tion of PKB-Thr308, a PDK1 substrate (Bayascas and Alessi,
2005). While this effect might indicate direct inhibition of
PI3K and/or PDK1, this is unlikely as these kinases are insen-
sitive to TORIN1 at concentrations <1 mM (Thoreen et al.,
2009). Moreover, the TORC2-catalysed phosphorylation of
PKB-Ser473 is known to facilitate the subsequent phosphory-
lation of PKB-Thr308 by PDK1 and this interaction suggests
that inhibition of TORC2 may also restrict the phosphoryla-
tion of PKB-Thr308 (Biondi et al., 2001; Sarbassov et al., 2005).
Our data are consistent with earlier results that showed that
TORIN1 (0.1 mM) inactivates TORC2 without inhibiting PI3K
or PDK1 (Thoreen et al., 2009). The fact that TORIN1 also
inactivated SGK1 therefore confirms that TORC2 is a critical
part of the mechanism that allows PI3K to activate this
protein kinase (Kobayashi and Cohen, 1999; Park et al., 1999;
García-Martínez and Alessi, 2008; Lu et al., 2010). TORIN1
abolished glucocorticoid-induced ENaC activity as effectively
as PI103 indicating that TORC2 is also important to the
hormonal control of these channels (see also Lu et al., 2010;
Mansley and Wilson, 2010a). Moreover, the fact that TORIN1
does not inhibit PI3K (Thoreen et al., 2009) predicts that
PIP2/3 will be present in the membranes of TORIN1-treated
cells and this is significant because these phospholipid
second messengers can activate ENaC by binding directly to
the channel complex (Blazer-Yost et al., 2004; Blazer-Yost and
Nofziger, 2005; Ma et al., 2007; Pochynyuk et al., 2008). The
fact that TORIN1 inactivates ENaC as effectively as PI103 thus
implies that PIP2/3 cannot support ENaC activity if TORC2 is
inactive and, while this does not exclude a role for PIP2/3 in
the control of ENaC, this mechanism must be of secondary
importance in H441 cells.
GSK650394 inactivated SGK1 without affecting PDK1,
TORC2 or PKB and these data confirm that this compound is
a selective inhibitor of SGK1 (Sherk et al., 2008; Mansley and
Wilson, 2010a). The fact that GSK650394 also abolished
dexamethasone-induced ENaC activity therefore shows that
SGK1 is critical to the glucocorticoid-dependent control of
these channels. It is particularly interesting that GSK650394
did not inhibit PKB since this protein kinase has been shown
to activate ENaC expressed heterologously in Xenopus oocytes
or Fisher rat thyroid cells, and it has been suggested that PKB
might be involved in the hormonal control of Na+ transport
via ENaC (Lee et al., 2007; Diakov et al., 2010). Although the
present data do not exclude this possibility, they show that
PKB cannot maintain ENaC activity independently of SGK1
in dexamethasone-stimulated H441 cells.
Figure 9
Effects of GSK650394 upon a-, b- and g-ENaC expression in dexamethasone-treated (0.2 mM, ~24 h) cells. Total and surface-exposed proteins
were from dexamethasone-treated (0.2 mM, ~24 h) control cells and from cells exposed to 10 mM GSK650394 for the final 3 h of the incubation
period were analysed as described in Figure 5. (A) Western blot showing the results of an individual experiment; bars to the right indicate the
approximate position of the appropriate molecular weight markers. (B) Densitometric analysis showing the pooled data from four independent
experiments (mean  SEM). *P < 0.05, significant effects of GSK650394, Student’s paired t-test.
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Glucocorticoid-induced changes in
ENaC expression
Detectable levels of a-, b- and g-ENaC were present in total
protein from glucocorticoid-deprived cells and the fact these
cells do not display amiloride-sensitive currents (present
study, Clunes et al., 2004; Brown et al., 2008; Althaus et al.,
2010) cannot, therefore, be attributed to the absence of
ENaC. Dexamethasone (24 h) increased the overall expres-
sion of a- and b-ENaC, but not g-ENaC, and this accords with
earlier work that has shown that this synthetic glucocorticoid
increases the abundance of mRNA encoding a- and b-ENaC in
H441 cells (Ramminger et al., 2004; Thomas et al., 2004).
Glucocorticoids can therefore control the expression of a-
and b-ENaC and, while the mechanism underlying the regu-
lated expression of b-ENaC is unclear, the effect on a-ENaC
seems to be mediated by glucocorticoid-response elements in
the a-ENaC gene promoter (see Itani et al., 2002; Thomas and
Itani, 2004; McTavish et al., 2009).
While the b-ENaC antibody recognized only a single
band, a- and g-ENaC antibodies each identified two bands in
total protein derived from glucocorticoid-deprived and
dexamethasone-stimulated cells. This observation is consis-
tent with reports that the post translational processing of a-
and g-ENaC, but not b-ENaC, involves cleavage by intracellu-
lar and extracellular proteases (see Vallet et al., 1997;
Vuagniaux et al., 2002; Hughey et al., 2003; 2004; Caldwell
et al., 2004; 2005; Myerburg et al., 2006; 2010; Diakov et al.,
2008; Passero et al., 2008; Rossier and Stutts, 2009; Tan et al.,
2011). Since these proteases act at different sites, the process-
ing of these channel subunits generates a complex popula-
tion of proteolytic fragments. The antibodies used in the
present study were all directed against N-terminal sequences
and molecular weights, which we now report are broadly
consistent with the pattern of a- and g-ENaC cleavage
described by Rossier and Stutts, (2009). Although it has been
suggested that the cleavage of a- and g-ENaC is critical for the
formation of active channels, we were unable to detect any
effect of dexmethasone that was consistent with increased
cleavage of these subunits despite the fact that this hormone
clearly induced an amiloride-sensitive Na+ current. However,
the data supporting this model are almost entirely derived
from studies of heterologously expressed ENaC subunits
incorporating synthetic epitopes (e.g. FLAG) that facilitate
the identification of cleavage products. While proteases and
protease inhibitors clearly modify electrogenic Na+ transport
in absorptive cells and tissues (see, e.g. Myerburg et al., 2006;
Lazrak et al., 2009; Tan et al., 2011), few authors have
attempted to correlate ENaC activity with changes to the
cleavage of endogenous subunits. It is possible that pro-
teolytically cleaved forms of endogenous ENaC are present at
a level too low to be detected by conventional methods
(Myerburg et al., 2010).
Analysis of surface-exposed proteins showed that a-, b-
and g-ENaC were all present in the membranes of
glucocorticoid-deprived and dexamethasone-stimulated cells
and, while both forms of a-ENaC were detected, only the
lighter form of g-ENaC was present in this protein pool.
Under our experimental conditions the 90 kDa form of
g-ENaC, which may correspond to the full length protein
(Rossier and Stutts, 2009), appears to be confined to the
Figure 10
Dexamethasone causes only a transient increase in SGK1 activity. (A)
Typical Western blots showing the effects of dexamethasone
(0.2 mM, 0–6 h) upon the abundance of Thr346/356/366-phosphorylated
(upper panel) and total (lower panel) n-myc downstream regulated
gene 1 protein (NDRG1). (B) Densitometric analysis showing the
pooled data from six such experiments. (C) Typical blots showing
the results of experiments that used the same protocol to explore the
effects of dexamethasone (0.2 mM, 0–6 h) upon the abundance of
Ser473-phosphorylated (upper panel) and total (lower panel) PKB. (D)
Densitometric analysis showing the pooled data from six such experi-
ments. (E) Typical Western blots showing the effects of short (3h) and
long-term (~24 h) dexamethasone exposure (0.2 mM) upon the
abundance of Thr346/356/366-phosphorylated and total NDRG1. (F)
Densitometric analysis showing the pooled data from five such
experiments. (G) Typical Western blots showing the effects of
short- (3 h) and long-term (~24 h) dexamethasone stimulation
(0.2 mM) upon the abundance of Ser473-phosphorylated (upper
panel) and total PKB (lower panel).; essentially identical data were
obtained in four independent experiments. (H) Densitometric analy-
sis showing the pooled data from five such experiments. All data are
mean  SEM. †P < 0.001, one-way ANOVA with Bonferroni post hoc
test; ***P < 0.001, Student’s paired t-test, significant effects of
dexamethasone.
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intracellular compartment. Although dexamethasone (~24 h)
increased the surface expression of a-ENaC, this effect was of
similar magnitude to the increase in overall expression. More-
over, prolonged (24 h) exposure to dexamethasone had no
effect upon the surface abundance of b-ENaC, and caused
only a modest increase in the surface expression of NaC. The
present data do not, therefore, support the hypothesis that
glucocorticoid-induced (~24 h) epithelial Na+ currents are due
to coordinated increases in the surface abundance of a-, b-
and g-ENaC (Blazer-Yost et al., 1998; 2003; Record et al., 1998;
De La Rosa et al., 1999; 2003; Păunescu et al., 2000; Debon-
neville et al., 2001).
Exposing dexamethasone-treated (24 h) cells to PI103,
TORIN1 and GSK650394 reduced the surface abundance of
g-ENaC and, because this action was not mimicked by rapa-
mycin, the dexamethasone-induced increase in the surface
expression of this subunit seems to be dependent upon the
PI3K – TORC2 – SGK1 pathway. This accords well with earlier
work (Blazer-Yost et al., 1998; 2003; Record et al., 1998; De La
Rosa et al., 1999; 2003; Păunescu et al., 2000; Debonneville
et al., 2001). However, PI103, TORIN1 or GSK650394 also
reduced the amount of the 95 kDa form of a-ENaC that was
present in the total and surface-exposed protein pools sug-
gesting that the PI3K–TORC2–SGK1 pathway is involved in
the control of a-ENaC synthesis (Boyd & Náray-Fejes-Tóth,
2005; Zhang et al., 2007; Reisenauer et al., 2009). However,
most of these compounds also inhibit TORC1 and it is there-
fore interesting that rapamycin, a selective TORC1 inhibitor
(Bain et al., 2007), also reduced the abundance of a-ENaC
(95 kDa). It is possible that TORC1 may also contribute to the
Figure 11
Brief (3 h) stimulation with dexamethasone increases the surface abundance of epithelial Na+ channel subunits (a-, b- and g-ENaC). (A) Typical
Western blots showing the effects of dexamethasone (0.2 mM, 3 h) upon the surface abundance of epithelial Na+ channel a, b and g subunits (a-,
b- and g-ENaC) both under control conditions and in the presence of 10 mM GSK650394 (GSK). (B) Densitometric analysis of the data (mean 
SEM) from four independent experiments. ***P < 0.001, significant differences between glucocorticoid-deprived and dexamethasone-stimulated
cells,; †P < 0.05 significant effects of GSK650394, one-way ANOVA with Bonferroni post hoc test.
Figure 12
Effects of brief (~3 h) and prolonged (~24 h) stimulation of dexamethasone upon epithelial Na+ channel activity. (A) Relationships between
amiloride-sensitive membrane current (IAmil, mean  SEM) and holding potential (VHold) quantified in glucocorticoid-deprived cells (Dex.-free,
n = 3, Cm = 47.7  7.2 pF; Ra = 30.7  9.1 MW) and in cells that had been exposed to 0.2 mM dexamethasone for ~3h (~3 h Dex., n = 5,
Cm = 33.6  2.3 pF; Ra = 30.7  4.8 MW) or ~24 h (~24 h Dex., n = 5,Cm = 48.0  3.0pF;Ra = 19.3  2.1 MW). (B) Values of IAmil (-82 mV) derived
by further analysis of these data. †P < 0.05, significantly different from corresponding values in glucocorticoid-free and in ~3 h Dex.-treated cells,
one-way ANOVA with Bonferroni post hoc test.
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control of a-ENaC expression and, in this context, it is rel-
evant that rapamycin has also been shown to disrupt the
dexamethasone-induced activation of ENaC in renal epithelia
(Mansley and Wilson, 2010a). However, none of the com-
pounds tested in the present study had a discernible effect
upon the expression of the 75 kDa form of a-ENaC, and the
present data also show that rapamycin-induced inhibition of
TORC1 did not suppress ENaC activity in H441 cells. The
physiological significance of the effects on the 95 kDa form of
a-ENaC is therefore not clear.
Brief (3 h) stimulation with dexamethasone
Although dexamethasone clearly activated SGK1, this
response was not associated with any change to the activity
of TORC2, and the situation seen in H441 cells is therefore
similar to that documented for renal epithelia where the
dexamethasone-induced activation of SGK1 seems to reflect
de novo synthesis of SGK1 protein (Wang et al., 2001;
Gonzalez-Rodriguez et al., 2007). However, as the nascent
protein is catalytically inactive, the PI3K–TORC2 pathway is
needed to phosphorylate SGK1-Ser422 and confer catalytic
activity upon the newly synthesized protein (Kobayashi and
Cohen, 1999; Park et al., 1999; García-Martínez and Alessi,
2008; Lu et al., 2010).
While undertaking these studies we noted glucocorticoid-
deprived and dexamethasone-stimulated (24 h) cells often
appeared to display very similar levels of NDRG1-Thr346/356/366
phosphorylation, and this observation (see also Inglis et al.,
2009) prompted us to compare the effects of brief (3 h) and
prolonged (24 h) dexamethasone stimulation upon the phos-
phorylation of these residues. These studies confirmed that
brief exposure to dexamethasone did increase SGK1 activity
without altering the activity of TORC2, but also showed that
prolonged (24 h) stimulation had no apparent effect upon
the activity of either kinase. Despite the sustained activation
of ENaC, the present data therefore suggest that SGK1 activity
returns to its basal level after ~24 h continuous exposure to
dexamethasone. Moreover, experiments that explored the
effects of brief (3 h) exposure to dexamethasone upon the
surface abundance of ENaC subunits showed that the period
of increased SGK1 activity was associated with an unambigu-
ous increase in the surface abundance of a-, b- and g-ENaC.
Furthermore, this response was abolished by GSK650394 and
it is therefore clear that SGK1 does provide a mechanism that
allows hormonal control over the surface expression of ENaC
subunits. However, despite this clear finding, electrophysi-
ological studies showed that brief (3 h) exposure to dexam-
ethasone did not induce Na+ currents while studies of cells
exposed to dexamethasone for ~24 h confirmed the sustained
activation of endogenous ENaC as described earlier.
Significance of present findings
The conceptual model almost invariably used to explain the
role of SGK1 in the control of epithelial Na+ absorption
(Blazer-Yost et al., 1998; 2003; Record et al., 1998; De La Rosa
et al., 1999; 2003; Păunescu et al., 2000; Debonneville et al.,
2001) predicts (i) that glucocorticoid-induced Na+ currents
will depend upon SGK1; and (ii) that the magnitude of this
Na+ current will correlate with the activity of SGK1 and with
the abundance of ENaC subunits at the cell surface. Although
data from the present study clearly verifies the first of these
statements, they also show that the effects of dexamethasone
upon SGK1 activity and the surface expression of ENaC sub-
units are transient and it is therefore clear that the sustained,
SGK1-dependent activation of ENaC seen in glucocorticoid-
stimulated H441 cells (present study Clunes et al., 2004;
Brown et al., 2008; Althaus et al., 2010) cannot be attributed
to SGK1-dependent changes to the surface abundance of
ENaC subunits. Studies of heterologously expressed ENaC
have suggested that SGK1 can control membrane Na+ current
via a mechanism that does not appear to involve the recruit-
ment of additional channel subunits to the membrane, and
this response is dependent upon an SGK1-consensus motif in
the C-terminal region of a-ENaC. It has been suggested that
SGK1 may contribute to the control of ENaC activity by
directly phosphorylating a-ENaC (Diakov and Korbmacher,
2004). However, this mechanism is unlikely to explain the
sustained activation of ENaC reported here because our data
indicate that glucocorticoid-induced SGK1 activity is not
sustained.
The signalling pathways that allow glucocorticoids to
evoke responses in pulmonary epithelia are complex (Barnes,
2011) and the present data show that the mechanisms that
allow these hormones to evoke sustained activation of ENaC
are not understood fully. Clarifying the mechanisms under-
lying this control over membrane Na+ conductance may
facilitate the developments of novel therapies for respiratory
distress and pulmonary oedema.
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